Success Metrics

Clinical Success Rate

83.3%

Based on 5 completed trials

Completion Rate

83%(5/6)

Active Trials

2(17%)

Results Posted

100%(5 trials)

Terminated

1(8%)

Phase Distribution

Ph phase_1

67%

Ph phase_2

33%

Phase Distribution

Early Stage

Mid Stage

Late Stage

Phase Distribution12 total trials

Phase 1Safety & dosage

8(66.7%)

Phase 2Efficacy & side effects

4(33.3%)

Highest Phase Reached

Phase 2

Trial Status & Enrollment

Completion Rate

83.3%

5 of 6 finished

Non-Completion Rate

16.7%

1 ended early

Currently Active

trials recruiting

Total Trials

all time

Status Distribution

Active(2)

Completed(5)

Terminated(1)

Other(4)

Detailed Status

Completed5

unknown4

Recruiting2

Terminated1

Development Timeline

Analytics

Development Status

Total Trials

Active

Success Rate

83.3%

Most Advanced

Phase 2

Trials by Phase

Phase 18 (66.7%)

Phase 24 (33.3%)

Trials by Status

recruiting217%

completed542%

terminated18%

unknown433%

Recent Activity

2 active trials

Showing 5 of 12

recruitingphase_1

CD19-Directed Chimeric Antigen Receptor Autologous T Cells (CART19) for Lupus

NCT06839976

recruitingphase_1

CD19-directed CAR-T Cell Therapy for R/R Acute Leukemia and Lymphoma

NCT06101381

unknownphase_1

CART-19 T Cell in CD19 Positive Relapsed or Refractory Acute Myeloid Leukemia (AML)

NCT03896854

completedphase_1

CART19 to Treat B-Cell Leukemia or Lymphoma That Are Resistant or Refractory to Chemotherapy

NCT01029366

completedphase_2

Phase IIa Study of Redirected Autologous T Cells Engineered to Contain Anti-CD19 Attached to TCRz and 4-Signaling Domains in Patients With Chemotherapy Relapsed or Refractory CD19+ Lymphomas

NCT02030834

View all 12 trials

Clinical Trials (12)

Showing 12 of 12 trials

NCT06839976Phase 1

CD19-Directed Chimeric Antigen Receptor Autologous T Cells (CART19) for Lupus

Recruiting

NCT06101381Phase 1

CD19-directed CAR-T Cell Therapy for R/R Acute Leukemia and Lymphoma

Recruiting

NCT03896854Phase 1

CART-19 T Cell in CD19 Positive Relapsed or Refractory Acute Myeloid Leukemia (AML)

Unknown

NCT01029366Phase 1

CART19 to Treat B-Cell Leukemia or Lymphoma That Are Resistant or Refractory to Chemotherapy

Completed

NCT02030834Phase 2

Phase IIa Study of Redirected Autologous T Cells Engineered to Contain Anti-CD19 Attached to TCRz and 4-Signaling Domains in Patients With Chemotherapy Relapsed or Refractory CD19+ Lymphomas

Completed

NCT02030847Phase 2

Study of Redirected Autologous T Cells Engineered to Contain Anti-CD19 Attached to TCR and 4-1BB Signaling Domains in Patients With Chemotherapy Resistant or Refractory Acute Lymphoblastic Leukemia

Completed

NCT01747486Phase 2

Dose Optimization Trial of CD19 Redirected Autologous T Cells

Completed

NCT01551043Phase 1

Allo CART-19 Protocol

Terminated

NCT01626495Phase 1

Phase I/IIA Study of CART19 Cells for Patients With Chemotherapy Resistant or Refractory CD19+ Leukemia and Lymphoma

Completed

NCT03101709Phase 1

The Safety and Efficacy of CART-19 Cells in Relapse and Refractory Patients With CD19+ B-cell Lymphoma